LENZ THERAPEUTICS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
LENZ THERAPEUTICS, INC. (LENZ) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $94.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $45.14M, a 22.33% decline year-over-year.
- LENZ THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $49.23M, a 5.48% decline year-over-year.
- LENZ THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $43.34M, a 24.18% increase year-over-year.
- LENZ THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $52.41M, a 138.24% increase year-over-year.
- LENZ THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $205.96M, a 134.31% increase from fiscal 2024.
- LENZ THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $87.90M, a 290.67% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $22.50M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $94.38M 10-Q · filed 2026-08-11 | $137.72M derived: sum of 3 quarters · filed 2026-08-11 | $190.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $49.23M 10-Q · filed 2026-05-11 | $92.58M derived: sum of 2 quarters · filed 2026-05-11 | $144.99M derived: sum of 3 quarters · filed 2026-05-11 | $203.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $43.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $95.75M derived: sum of 2 quarters · filed 2026-03-24 | $153.87M derived: sum of 3 quarters · filed 2026-08-11 | $205.96M 10-K · filed 2026-03-24 |
| 2025-09-30 | $52.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $110.53M derived: sum of 2 quarters · filed 2026-08-11 | $162.62M 10-Q · filed 2025-11-05 | $197.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $58.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $110.21M 10-Q · filed 2026-08-11 | $145.11M derived: sum of 3 quarters · filed 2026-08-11 | $167.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $52.09M 10-Q · filed 2026-05-11 | $86.99M derived: sum of 2 quarters · filed 2026-05-11 | $108.99M derived: sum of 3 quarters · filed 2026-05-11 | $121.99M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $34.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $56.90M derived: sum of 2 quarters · filed 2026-03-24 | $69.90M derived: sum of 3 quarters · filed 2026-03-24 | $87.90M 10-K · filed 2026-03-24 |
| 2024-09-30 | $22.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $35.00M derived: sum of 2 quarters · filed 2025-11-05 | $53.00M 10-Q · filed 2025-11-05 | $74.00M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $31.00M 10-Q · filed 2025-07-30 | $52.00M derived: sum of 3 quarters · filed 2025-07-30 | $53.50M derived: sum of 4 quarters · filed 2025-07-30 |
| 2024-03-31 | $18.00M 10-Q · filed 2025-05-07 | $39.00M derived: sum of 2 quarters · filed 2025-05-07 | $40.50M derived: sum of 3 quarters · filed 2025-05-07 | $40.50M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $22.50M derived: sum of 2 quarters · filed 2025-03-19 | $22.50M derived: sum of 3 quarters · filed 2025-03-19 | $22.50M 10-K · filed 2025-03-19 |
| 2023-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.50M derived: sum of 2 quarters · filed 2024-11-06 | $1.50M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |